Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1119]
News [2438]
Articles [146]
Editorials [8]
Conferences [102]
elearning [12]
Treatment options in castration-resistant prostate cancer: Expert discussion
Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane...
Treatment options in castration-resistant prostate cancer: Expert discussion ( Prof Karim Fizazi, Prof Eleni Efstathiou, Dr Bertrand Tombal and Prof Stephane Oudard )
29 Sep 2014
New horizons in prostate cancer: The final results of the COU-302 abiraterone...
Prof Charles Ryan and Prof Gordon McVie
New horizons in prostate cancer: The final results of the COU-302 abiraterone study ( Prof Charles Ryan and Prof Gordon McVie )
28 Sep 2014
Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the...
Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA
Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )
23 Sep 2014
Additional treatment options impact first-line treatment of mRCC: No
Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France
Additional treatment options impact first-line treatment of mRCC: No ( Prof Stéphan Oudard - Hôpital Européen Georges Pompidou, Paris, France )
23 Sep 2014
Current treatment options in mRCC
Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA
Current treatment options in mRCC ( Dr Thomas Hutson - Baylor University Medical Center, Dallas, USA )
23 Sep 2014
Discussion: Additional treatment options impact first-line treatment of mRCC
Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán
Discussion: Additional treatment options impact first-line treatment of mRCC ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )
23 Sep 2014
Additional treatment options impact first-line treatment of mRCC: Yes
Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium
Additional treatment options impact first-line treatment of mRCC: Yes ( Prof Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )
23 Sep 2014
What have we learned? Expert perspectives
Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán
What have we learned? Expert perspectives ( Dr Thomas Hutson; Prof Stéphan Oudard; Prof Patrick Schöffski; Dr Ignacio Durán )
23 Sep 2014
From clinical trial to clinical practice: Evidence from the real world
Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid...
From clinical trial to clinical practice: Evidence from the real world ( Dr Ignacio Durán - Associate Director of Clinical Research at START Madrid, Madrid, Spain )
23 Sep 2014
ecancermedicalscience editor's choice for September 2014
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for September 2014 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
18 Sep 2014
Global prostate cancer disparities and the parts both genetic and behavioural...
Dr Folakemi Odedina - College of Pharmacy, University of Florida, Gainesville...
Global prostate cancer disparities and the parts both genetic and behavioural factors play ( Dr Folakemi Odedina - College of Pharmacy, University of Florida, Gainesville, USA )
28 Aug 2014
Networking and collaborating across borders in sub-Saharan Africa
Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer...
Networking and collaborating across borders in sub-Saharan Africa ( Dr Shubhra Ghosh - Project Director of Global Programs, MD Anderson Cancer Centre, Houston, USA )
26 Jun 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation